Ernexa Therapeutics Inc. Finite-Lived Intangible Assets, Gross
Ernexa Therapeutics Inc. (ERNA) had Finite-Lived Intangible Assets, Gross of $667.00 thousand as of 2019-12-31, per its 10-K filed 2020-03-19.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsGross · last filed 2020-03-19
- 2019-12-31: Finite-Lived Intangible Assets, Gross $667.00K.
- 2018-12-31: Finite-Lived Intangible Assets, Gross $1.00M.
- 2017-12-31: Finite-Lived Intangible Assets, Gross $937.00K.
- 2016-12-31: Finite-Lived Intangible Assets, Gross $984.00K.
| Period end | Finite-Lived Intangible Assets, Gross | Finite-Lived Intangible Assets, Gross as first filed |
|---|---|---|
| 2019-12-31 | $667.00K 10-K · filed 2020-03-19 | |
| 2018-12-31 | $1.00M 10-K · filed 2020-03-19 | |
| 2017-12-31 | $937.00K 10-K · filed 2019-03-22 | |
| 2016-12-31 | $984.00K 10-K · filed 2017-03-09 | |
| 2015-12-31 | $984.00K 10-K · filed 2017-03-09 | $974.00K 10-K · filed 2016-03-15 |
| 2014-12-31 | $1.04M 10-K · filed 2016-03-15 | |
| 2013-12-31 | $2.80M 10-K · filed 2015-03-27 | |
| 2012-12-31 | $2.83M 10-K · filed 2014-03-31 | |
| 2011-12-31 | $2.71M 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |